期刊文献+

卵巢浆液性肿瘤中Pax8和Tubulin的表达及意义 被引量:5

Expression of Pax8 and Tubulin in ovarian serous tumors and their significances
在线阅读 下载PDF
导出
摘要 目的探讨Pax8和Tubulin在卵巢浆液性肿瘤中的表达及意义。方法采用免疫组化SP法检测28例正常卵巢组织、38例卵巢良性浆液性囊腺瘤、34例卵巢交界性浆液性肿瘤和38例卵巢浆液性癌中Pax8、Tubulin的表达,并复习相关文献。结果正常卵巢上皮中Pax8、Tubulin均呈阴性,卵巢良性浆液性囊腺瘤、交界性浆液性肿瘤、浆液性癌中Pax8、Tubulin阳性率分别为78.9%和78.9%、100%和100%、94.7%和89.5%,Pax8在卵巢交界性浆液性肿瘤及浆液性癌组织中表达明显高于良性浆液性囊腺瘤组织(P<0.05),Tubulin在3种卵巢肿瘤中的表达差异无显著性(P>0.05),但存在表达部位的改变;Pax8表达与卵巢浆液性癌患者年龄、FIGO分期、病理学分级、淋巴结转移无关(P>0.05),Tubulin表达与浆液性癌病理学分级有关(P<0.05),Pax8、Tubulin的免疫组化评分比值大小与淋巴结转移密切相关(P<0.05)。结论 Pax8可能作为卵巢浆液性癌的标志分子,并为其临床靶向分子治疗提供实验依据;综合分析Pax8、Tubulin及二者免疫组化评分比值,对评估卵巢浆液性癌患者的病理学分级、淋巴结转移情况具有参考意义。 Purpose To investigate the expression of Pax8 and Tubulin protein in ovarian serous tumors and their clinicopathologic significances. Methods Immuohistochemistry was used to detect the expressions of Pax8 and Tubulin protein in 28 normal ovarian epithelium, 38 ovarian serous cystadenoma, 34 ovarian serous borderline tumor, 38 ovarian serous cancer samples and the relevant literature is reviewed. Results Pax8 and Tubulin in normal ovarian epithelium were not expressed, while the positive rates of Pax8 and Tubulin in ovarian serous cystadenoma, ovarian serous borderline tumor, ovarian serous cancer samples were 78.9% and 78.9% , 100% and 100%, 94. 7% and 89.5% , respectively. Immunohistochemical staining was scored which shows the expression of Pax8 in ovarian serous borderline tumor, ovarian serous cancer samples is significantly higher than ovarian serous cystadenoma ( P 〈 0. 05 ) , and Tubulin in the three ovarian tumors is not different ( P 〉 0. 05 ) , but there is a change of the expression sites of Tubulin. The expression level of Pax8 is not associated with the age of ovarian serous cancer patients, FIGO stage, pathological grade, lymph node metastasis (P 〉 0. 05 ) , Tubulin expression is correlated with pathological grade ( P 〈 0. 05 ). The mmunohistochemical scores ratio of Pax8 and Tubulin is related to lymph node metastasis ( P 〈 0. 05 ). Conclusion Pax8 expression may be "used as a molecular marker and clinical treatment target of ovarian serous cancer. There is an important reference value to assess the histological grade, lymph node metastasis of ovarain serous cancer patients by comprehensive analysis of Pax8, Tubulin and the ratio of Pax8 and Tubulin.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2014年第7期713-716,共4页 Chinese Journal of Clinical and Experimental Pathology
基金 国家自然科学基金(81001168 81272881) 安徽省2014年度重点立项项目(1301043053)
关键词 卵巢肿瘤 浆液性癌 分泌细胞 纤毛细胞 Pax8 TUBULIN ovarian neoplasm serous cancer secretory cell ciliated cell Pax8 Tubulin
作者简介 徐兵,男,硕士研究生。E—mail:529857485@qq.com 胡卫平,女,教授,通讯作者。E-mail:syhwp@163.com
  • 相关文献

参考文献18

  • 1Siegel R,Naishadha D,Jemal A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30.
  • 2Muratovska A,Zhou C,He S,et al.Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival[J].Oncogene,2003,22(39):7989-97.
  • 3Li J,Abushahin N,Pang S,et al.Tubal origin of ‘ovarian' low-grade serous carcinoma[J].Mod Pathol,2011,24(11):1488-99.
  • 4Zhao W,Zhou Y,Xu H,et al.Snail family proteins in cervical squamous carcinoma: Expression and significance[J].Clin Invest Med,2013,36(4):E223-33.
  • 5Zhang Y,Hu C F,Chen J,et al.LATS2 is de-methylated and overexpressed in nasopharyngeal carcinoma and predicts poor prognosis[J].BMC Cancer,2010,10:538.
  • 6Haynes C M,Sangoi A R,Pai R K.PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens[J].Cancer Cytopathol,2011,119(3):193-201.
  • 7Knoepp S M,Kunju L P,Roh M H.Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology[J].Diagn Cytopathol,2012,40(8):667-72.
  • 8Nikiforov Y E.Molecular diagnostics of thyroid tumors[J].Arch Pathol Lab Med,2011,135(5):569-77.
  • 9Mittag J,Winterhager E,Bauer K,et al.Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacment therapy[J].Endocrinology,2007,148(2):719-25.
  • 10Cheung H W,Cowley G S,Weir B A,et al.Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer[J].Proc Natl Acad Sci USA,2011,108(30):12372-7.

同被引文献41

  • 1胡文娟,王仁杰.PAX2、PAX8、P53蛋白在低级别、高级别浆液性卵巢癌中的表达研究[J].医学信息(医学与计算机应用),2014,0(19):668-668. 被引量:1
  • 2姜会霞.头颈部癌瘤联合根治术围手术期护理[J].中国误诊学杂志,2005,5(2):367-368. 被引量:2
  • 3Tornos C,Soslow R,Chen S,黄文斌(摘译),陈洁宇(摘译),周晓军(审校).WT1、CA125和GCDFP-15在卵巢原发性癌和转移性乳腺癌鉴别诊断中的价值[J].临床与实验病理学杂志,2005,21(6):742-742. 被引量:10
  • 4Wang Y,Wang Y,Li J,et al. PAX8: a sensitive and spe- cific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy [J]. J Hematol Oncol, 2013,6: 60.
  • 5Ordonez NG. Value of PAX 8 immunostaining in tumor diagnosis:a review and update [J]. Adv Anat Pathol,2012, 19(3) : 140-151.
  • 6Xiang L, Kong B. PAX8 is a novel marker for differentiat- ing between various types of tumor,particularly ovarian epithelial carcinomas [J]. Oncol Lett, 2013,5 (3) : 735-738.
  • 7Liliac L,Carcangiu ML,Canevari S,et aL The value of PAX8 and WT1 molecules in ovarian cancer diagnosis [J]. Rom J Morphol Embryo1,2013,54( 1 ) : 17-27.
  • 8Laury AR,Perets R,Piao H,et al. A comprehensive analy- sis of PAX8 expression in human epithelial tumors [J]. Am J Surg Pathol, 2011,35(6) : 816-826.
  • 9Zhao L; Guo M, Sneige N, et al. Value of PAX8 and WT1 Immunostaining in confirming the ovarian origin of metastatic carcinoma in serous effusion specimens [J]. Am J Clin Pathol,2012,137(2) :304-309.
  • 10Tong GX,Devaraj K,Hamele-Bena D,et al. PaxS:a mark- er for carcinoma of Mtillerian origin in serous effusions [J]. Diagn Cytopathol, 2011,39 (8) : 567-574.

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部